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Abstract
Background: Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid found in certain coffee (Coffea) species,
fruits (Cupuacu [Theobroma grandiflorum]), and tea (Camellia assamica, var. kucha) that has anti-inflammatory,
analgesic, and neuro-locomotor properties. Recent preliminary research has also reported increased feelings of
energy, reduced fatigue, and strong effects on improving focus, concentration, and motivation to exercise. The
purpose of this study was to examine the safety and non-habituating effects of TeaCrine®, a nature-identical,
chemically equivalent bioactive version of theacrine.
Methods: Sixty healthy men (mean ± SD age, height, weight: 22.9 ± 4.7 years, 183.5 ± 9.2 cm, 86.5 ± 13.7 kg) and
women (22.3 ± 4.5 years, 165.2 ± 12.3 cm, 69.0 ± 17.4 kg) were placed into one of three groups: placebo (PLA,
n = 20), 200 mg TeaCrine® (LD, n = 19) or 300 mg Teacrine® (HD, n = 21) and ingested their respective supplement
once daily for 8 weeks. Primary outcomes were fasting clinical safety markers (heart rate, blood pressure, lipid
profiles, hematologic blood counts, biomarkers of liver/kidney/immune function) and energy, focus, concentration,
anxiety, motivation to exercise, and POMS measured prior to daily dosing to ascertain potential tachyphylactic
responses and habituation effects. Data were analyzed via two-way (group × time) ANOVAs and statistical
significance was accepted at p < 0.05.
Results: All values for clinical safety markers fell within normal limits and no group × time interactions were noted.
No evidence of habituation was noted as baseline values for energy, focus, concentration, anxiety, motivation to
exercise, and POMS remained stable in all groups across the 8-week study protocol.
Conclusions: These findings support the clinical safety and non-habituating neuro-energetic effects of TeaCrine®
supplementation over 8 weeks of daily use (up to 300 mg/day). Moreover, there was no evidence of a tachyphylactic
response that is typical of neuroactive agents such as caffeine and other stimulants.
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Background
TeaCrine® is a nature-identical, chemically equivalent
bioactive version of theacrine. Theacrine is a purine
alkaloid that is converted from caffeine by hydration,
oxidation and methylation [1] and it is thought to
influence the central nervous system as a neuroactive
ingredient. Theacrine is the primary extract from the
cultivated tea plant Cameilla kucha, and has recently
been studied as an ingredient that may have various
therapeutic and medicinal uses. Acute supplementation is
theorized to enhance mood state, increase energy produc-
tion, heighten mental focus, and strengthen motivation.
In various rodent models, theacrine has been shown
to increase dopamine levels, decrease ROS (reactive
oxidative species) and inflammation, decrease adenosine,
and modulate other neurotransmitters. However, there is
limited research available on chronic theacrine supple-
mentation in humans, with only one poster presentation
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(single dose) supplementation. Moreover, to our know-
ledge there is no published research in humans that
examines the safety of chronic theacrine supplementation.
The current research on theacrine is isolated in rodent
models with the exception of only conference proceed-
ings poster currently published on one acute dose study
that aimed to assess the cognitive and psychometric
responses in humans. The preliminary abstract data in
this trial indicated that acute supplementation of 200 mg
of TeaCrine® had beneficial effects on increased energy
and reductions in fatigue [2]. Although preliminary, this
data along with the various data in animals is interesting
and suggests a possible role for the utilization of thea-
crine as a therapeutic supplement for augmenting cogni-
tive and physical performance [3]. In regards to safety of
ingestion, there are currently no clinical trials that have
looked at the potential effects, positive or negative, that
TeaCrine® supplementation may have on hemodynamics,
blood chemistry profiles including liver function, lipid
panels, complete blood counts (CBC), etc. in humans.
Animal model research has evaluated the toxicity of
theacrine and determined it is safe for ingestion [4] and
has not been shown to have any negative effects on heart
rate and blood pressure in rats [5].
Because theacrine is a caffeine derivative and extracted
from tea, its potential effects on body composition are
worth exploring. The inclusion of caffeine and tea ex-
tracts, primarily green tea in the form of EGCG, is a
commonly studied method to influence energy expend-
iture and body composition. Recent research has shown
that ingestion of these types of ingredients in various
combinations can increase resting energy expenditure
[6], improve body composition [7], enhance exercise
performance [8], and improve cholesterol profiles [7]
while showing no ill effects on safety parameters [9].
Despite most of this data utilizing multi-ingredient for-
mulas, because of the nature of the compound it is of
interest to evaluate if theacrine has any similar effects on
body composition profiles.
Collectively, the limited availability of data on thea-
crine ingestion in human models has led to the research
questions being evaluated in this clinical trial, namely to
examine the effects of various doses of TeaCrine® on
safety (blood chemistry, hemodynamics, ECG function-
ing), mood profiles, and body composition. Additionally,
it is of interest to assess the dosing response on any
potential tachyphylactic and/or discontinuation effects
that are commonly seen with ingestion of caffeine and
other neuroactive stimulants.
Methods
Experimental approach to the problem
A randomized, placebo controlled, double-blind study was
used to compare the effects of consuming a low dose of
Teacrine® (TC-LD), a high dose of Teacrine® (TC-HD) or
a placebo (PLA) for 8 weeks on apparently healthy, recre-
ationally active, regular caffeine consuming, males and
females. The following dependent variables were assessed
to determine supplementation-induced differences based
on the three groups: clinical safety markers, heart rate,
blood pressure, questionnaires (VAS, Yale PAQ and POMS)
and body composition. Subjects were instructed not to
change their exercise habits or their standard dietary habits.
The design allowed for examination of the effects of
Teacrine® in a low and high dose with no diet or
exercise regimen manipulations.
Subjects
Sixty men and women (mean ± SD age, height, weight,
body fat percentage: 22.55 ± 4.6 years, 174.09 ± 12.4 cm,
77.47 ± 17.4 kg, 23.4 ± 9.9 %) participated in this study.
Subjects were not allowed to participate in this study if
they had any metabolic disorder including known; heart
disease, arrhythmias, diabetes, cancer; if they were taking
medications related to chronic disease; if they were
taking or had taken dietary supplements (other than
multi-vitamins and/or minerals) within 8 weeks prior
to enrollment; if they had participated in another
clinical trial within 8 weeks prior to enrollment; if
they had any known allergies or sensitivity to any ingredi-
ent in the test product; and, if they were currently preg-
nant, nursing or became pregnant during the duration of
the study. Subjects were asked to maintain their normal
dietary intake and exercise habits for the duration of the
study. Subjects meeting eligibility criteria were informed
of the requirements for the study and signed approved in-
formed consent statements in compliance with the guide-
lines of the Institutional Review Board at the University of
Mary Hardin-Baylor (UMHB). All anthropometric and
hemodynamic/ECG testing was conducted in the Human
Performance Laboratory (HPL) and all blood processing
was conducted in the Exercise Biochemistry Laboratory at
UMHB.
Baseline (T1) testing
Prior to the baseline session, subjects were instructed to
record all food intakes on dietary record forms for 3
days (3-d). At the end of the 3 days, diet logs were brought
back to the lab to be entered into Esha Food Processor
(ESHA Research, Salem, OR) for nutritional assessment.
For all testing sessions, subjects were instructed to refrain
from exercise for 48 h, abstain from smoking, caffeine,
tobacco as well as fast for 12-h prior to baseline testing
and refrain from alcohol consumption for 24 h. Subjects
were encouraged to consume plenty of water the day prior
to each testing session and to consume water upon waking
prior to reporting to the lab.
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The day of baseline testing (T1), subjects reported to
the HPL during their scheduled time (between the hours
of 0500–0800) to be weighed via TANITA electronic
scale (Model TBF-310, TANITA, Arlington Heights, IL)
and height measured using a SECA 242 instrument
(242, SECA, Hanover, MD). Resting heart rate (RHR)
and blood pressure (SBP & DBP) were obtained in a
rested and seated position via OMRON Digital Blood
Pressure Monitor (Model HEM-907XL, OMRON Health-
care, Inc. IL U.S.A.). HR, recorded as beats per minute,
SBP and DBP, recorded as mmHg, were measured at the
completion of the ECG. Body composition was deter-
mined using bioelectrical impedance analysis via InBody
(Model 770, InBody Co., Ltd, Cerritos, CA). For InBody
measurements, test-retest reliability in our lab are as
follows: Fat Mass: ICC = 0.99; Lean Mass: ICC = 0.99;
percent body fat: ICC = 0.998. All InBody tests were
conducted by the same technician and strict manufacturer
guidelines for calibration and testing procedures were
followed.
Electocardiogram (ECG)
Once body composition was completed, subjects per-
formed an electrocardiogram (ECG). Leads were placed
in standard clinical fashion to produce a 12 lead ECG
(I-III, V1-V6, aVR, aVL, aVF). Subjects remained in a
supine position for 5 min. Cardiac rhythm was moni-
tored through a Quinton Eclipse Premier Electrocar-
diograph (Cardiac Science Corporation, Bothell, WA).
Data was printed from the 12-lead ECG machine and
RR interval, RP interval, QRS duration, and QT inter-
val were recorded.
Blood collection protocol and questionnaires
Blood was collected from an antecubital vein with the
subject in a supine position. To negate diurnal variation
in hormonal status sampling was taken at the same time
for each of the testing days. Upon extracting the blood
into two 7.5 ml tiger top Vacutainer®, the sample was
inverted gently (5–6 times) and was sent to the blood
analysis room to allow time to clot and was centrifuged
for 15 min within 30–60 min at room temperature to
yield serum samples for complete metabolic and lipid
panel measures. A 4 mL purple top Vacutainer® was
drawn from the forearm vein and was mixed gently via
inversion and then refrigerated for CBC measurements.
All samples were then refrigerated and sent to Quest
(Quest Diagnostics Inc., Irvine, TX) for analysis. All
blood collection and processing protocols were in line
with the recommendations from Quest diagnostics to
ensure optimal samples for analysis.
After blood collection subjects were given the supple-
ment based on their randomly assigned group and told
to ingest the supplement with 8 fluid ounces of water
and remained in the HPL for 30 min to ensure no aller-
gic reaction occurred. Immediately after ingestion of the
supplement, subjects were given a symptoms survey,
Profile of Mood States (POMS), the Visual Analog Scale
(VAS) (including: energy, focus, concentration, sleep,
vigor, and motivation to exercise), and YALE Physical
Activity Survey (YALE) to establish baseline measures of
these dependent variables. The VAS was structured as a
15-cm scale that was labeled as “lowest possible” and
“highest possible” for each VAS variable as used in previ-
ous research [10, 11]. The YALE survey has been used in
various settings as a measure of physical activity [12, 13].
Supplementation protocol
Subjects were matched according to T1 body mass and
gender, then in a randomized, double-blind manner were
assigned to consume a low dose of 200 mg of TeaCrine®
(TC-LD) (n = 19, 23.5 ± 6 years, 175.6 ± 13.3 cm, 78 ±
18.4 kg, 23.4 ± 10 %BF), a higher dose of 300 mg of
TeaCrine® (TC-HD) (n = 21, 21.38 ± 2.3 years, 172.7 ±
12 cm, 77 ± 17.3 kg, 24 ± 10.2 %BF) or 300 mg of malto-
dextrin (PLA) (n = 20, 22.8 ± 4.7 years, 174 ± 12.1 cm, 77
± 17.2 kg, 22.3 ± 9.9 %BF) once per day, after breakfast
but before lunch, with 8 oz of water for the 8-week study
protocol. Dosing was selected based on previous re-
search that has been presented at the ISSN Annual
Meeting [2]. The terms high and low dose are relative to
what was utilized in this study and future research is
needed to truly establish what determines a true “high”
and “low” dose of TeaCrine®. Compliance of pill inges-
tion was monitored by research assistants every 2 weeks
in the HPL when subjects would return to get a new
2 week supply of pills for their respective treatment
group.
Follow-up testing and dietary intake
Throughout the 8-week protocol, subjects returned to
the HPL for follow-up testing at week 4 (T2) and week 8
(T3) and repeated identical testing procedures as dis-
cussed during T1 testing. Note that prior to T1 testing
subjects were instructed to record all food intakes on 3-
d dietary record forms. Subsequently, subjects were told
to maintain their diets as closely as possible to the previ-
ously 3-d recorded intakes (on T1). Dietary intakes
for calories and macronutrient profiles are displayed in
Table 1.
Statistics
Statistical analyses was performed using SPSS v22.0
(Chicago, IL, USA). An alpha level (α) of p ≤ 0.05 was used
to determine significance within or between groups.
Mixed-factorial ANOVA’s with repeated measures [group
(PLA ×TC-LD×TC-HD) × gender (M× F) × time (T1, T2,
T3)] were used for all dependent variables. If a significant
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[(time), (time*group), (time*group*gender)] interaction
was observed, additional post hoc analyses were per-
formed as follows: 1) for significant time effects, within-
group repeated measures ANOVAs with Bonferroni’s
corrections were performed, 2) for significant time*group
interactions, within-group repeated measures ANOVAs
with Bonferroni’s corrections, and one-way ANOVAs at
each time point with Tukey post hoc analyses were per-
formed, and 3) for significant time*group*gender interac-
tions, within-group repeated measures ANOVAs with
Bonferroni’s corrections were performed for each gender,
and one-way ANOVAs with Tukey post hoc analyses were
performed for each gender. Unless otherwise noted, data
are presented as mean ± SD.
Results
Effects of TeaCrine® on macronutrient intakes
The effects of each treatment on macronutrient intakes
are listed in Table 1. Analyses for protein/d revealed
a main effect for time (p = 0.04), but no time*group
interaction (p = 0.48). Split-plot analyses for protein/d
regarding time*group*gender interactions revealed no
interaction (p = 0.40). A Tukey’s post hoc for the main
time effect revealed a significant difference between T1
and T3 (p = 0.042); however, T1 and T3 comparisons
within each group revealed no significant differences
(p > 0.05). Analyses for kcal/d, carb/d and fat/d revealed
no main effect for time, time*group interaction or
time*group*gender interaction (data in Table 1).
Effects of TeaCrine® on body composition
The effects of each treatment on body composition are
listed in Fig. 1. Analyses for lean mass revealed a main
effect for time (p = 0.023), but no time*group interaction
(p = 0.99). Split-plot analyses for lean mass regarding
time*group*gender interactions revealed no interaction
(p = 0.19). Additional post hoc analyses revealed a main
effect between T1 and T2 (p = 0.037); however, T1 and
T2 comparisons within each group revealed no signifi-
cant differences (p > 0.05). Analyses for body weight, fat
mass and body fat percentage revealed no main effects
for time, time*group interactions or time*group*gender
interactions (Fig. 1).
Effects of TeaCrine® on clinical safety markers
Blood pressure, heart rate, and ECG variables
The effects of each treatment on cardiovascular safety
markers are listed in Tables 2 and 3. Analyses for heart
rate revealed a main effect for time (p = 0.032), but no
main effect for time*group interaction (p = 0.35). Split-
plot analyses for heart rate regarding time*group*gender
interactions revealed no interaction (p = 0.85). Additional
post hoc analyses revealed a main effect between T1
and T3 (p = 0.049); however, T1 and T3 comparisons
within each group revealed no significant differences
(p > 0.05). Analyses for SBP, DBP and Vent Rate re-
vealed no main effects for time, time*group interactions
or time*group*gender interactions (Table 2).
Analyses for p axis revealed no main effect for time
(p = 0.66), but revealed a main effect for time*group
Table 1 Macronutrient intakes
Variable T1 T2 T3 Time*group Time*group*gender
kcal/d
PLA 2054 ± 700 2132 ± 822 2128 ± 778 Time p = 0.11 G*T*Ge p = 0.17
LD 2469 ± 727 2450 ± 957 2155 ± 563 G*T p = 0.39
HD 2478 ± 1252 2395 ± 1139 2031 ± 763
Fat g/d
PLA 85 ± 30 83 ± 32 92 ± 50 Time p = 0.89 G*T*Ge p = 0.41
LD 101 ± 47 105 ± 50 104 ± 30 G*T p = 0.42
HD 100 ± 60 94 ± 55a 83 ± 35a
Protein g/d
PLA 106 ± 32 94 ± 28 96 ± 36 Time p = 0.04 G*T*Ge p = 0.40
LD 108 ± 62 101 ± 46 90 ± 34 G*T p = 0.48
HD 110 ± 69 108 ± 57 83 ± 48
Carb g/d
PLA 223 ± 109 320 ± 297 234 ± 91 Time p = 0.23 G*T*Ge p = 0.37
LD 284 ± 102 284 ± 119 266 ± 89 G*T p = 0.52
HD 282 ± 127 280 ± 148 235 ± 102
Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Superscript letters, different letters are significantly different at a given time point (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed
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Fig. 1 Between-treatment effects on body composition variables are illustrated in graph (a) Body mass, (b) Body fat mass, (c) Dry lean mass, and
(d) Body fat %. Abbreviations: PLA, Placebo; LD, Theacrine Low Dose; HD, Theacrine High Dose. There were no main effects of time, group*time
interactions or group*time*gender interactions for select body composition variables
Table 2 Cardiovascular safety markers, part I
Variable T1 T2 T3 Time*group Time*group*gender
SBP (mm Hg)
PLA 117 ± 15 116 ± 12 115 ± 13 Time p = 0.45 G*T*Ge p = 0.73
LD 116 ± 9 115 ± 8 116 ± 6 G*T p = 0.12
HD 118 ± 15 124 ± 12 122 ± 13
DBP (mm Hg)
PLA 69 ± 9 68 ± 9 68 ± 9 Time p = 0.58 G*T*Ge p = 0.89
LD 70 ± 7 67 ± 8 71 ± 8 G*T p = 0.53
HD 70 ± 8 68 ± 8 73 ± 8
Heart rate (beats/min)
PLA 60 ± 10 64 ± 8 63 ± 10 Time p = 0.032 G*T*Ge p = 0.85
LD 60 ± 15 59 ± 10a 63 ± 12a G*T p = 0.35
HD 59 ± 12 63 ± 10 64 ± 13
Vent Rate (breath/min)
PLA 60 ± 9 61 ± 10 62 ± 8 Time p = 0.43 G*T*Ge p = 0.67
LD 57 ± 13 59 ± 11 60 ± 13 G*T p = 0.10
HD 63 ± 12 59 ± 11 61 ± 11
Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Superscript letters, different letters are significantly different at a given time point (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed
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interaction (p = 0.033). Split-plot analyses for p axis
regarding time*group*gender interactions revealed no
interaction (p = 0.88). However, additional post hoc
analyses revealed no significant differences within
groups from T1 through T3. Moreover, one-way
ANOVAs at each time point revealed no differences
between each treatment. Analyses for ECG RR Inter-
val, ECG PR Interval, ECG QRS Duration, ECG QT
Interval, ECG QTc Interval, ECG QT Dispersion,
ECG R Axis and ECG T Axis revealed no main effects
for time, time*group interactions or time*group*gender
interactions (Table 3).
Table 3 Cardiovascular safety markers, part II
Variable T1 T2 T3 Time*group Time*group*gender
RR Interval (ms)
PLA 1011 ± 148 991 ± 147 976 ± 113 Time p = 0.23 G*T*Ge p = 0.68
LD 1095 ± 240 1041 ± 185 1035 ± 212 G*T p = 0.55
HD 987 ± 213 1043 ± 221 1007 ± 198
PR Interval (ms)
PLA 155 ± 25 155 ± 18 156 ± 20 Time p = 0.49 G*T*Ge p = 0.42
LD 153 ± 18 153 ± 20 154 ± 17 G*T p = 0.33
HD 150 ± 24 144 ± 24 143 ± 19
QRS Duration (ms)
PLA 95 ± 11 91 ± 22 96 ± 12 Time p = 0.32 G*T*Ge p = 0.25
LD 93 ± 12 93 ± 11 94 ± 11 G*T p = 0.41
HD 92 ± 13 92 ± 12 92 ± 12
QT Interval (ms)
PLA 428 ± 27 424 ± 31 424 ± 25 Time p = 0.33 G*T*Ge p = 0.38
LD 427 ± 40 424 ± 36 419 ± 38 G*T p = 0.36
HD 409 ± 26 614 ± 904 418 ± 38
QTc Interval (ms)
PLA 429 ± 17 426 ± 19 427 ± 22 Time p = 0.89 G*T*Ge p = 0.35
LD 421 ± 24 422 ± 22 419 ± 23 G*T p = 0.33
HD 414 ± 19 417 ± 20 419 ± 27
QT Dispersion (ms)
PLA 38 ± 25 33 ± 18 36 ± 42 Time p = 0.78 G*T*Ge p = 0.11
LD 35 ± 21 51 ± 90 38 ± 25 G*T p = 0.51
HD 41 ± 27 32 ± 21 32 ± 27
P Axis (degrees)
PLA 54 ± 31 65 ± 12 59 ± 25 Time p = 0.66 G*T*Ge p = 0.88
LD 52 ± 37 53 ± 37 53 ± 35 G*T p = 0.033
HD 61 ± 15 54 ± 19 59 ± 17
R Axis (degrees)
PLA 73 ± 32 78 ± 26 76 ± 33 Time p = 0.81 G*T*Ge p = 0.13
LD 74 ± 25 67 ± 33 72 ± 26 G*T p = 0.38
HD 85 ± 9 84 ± 9 84 ± 11
T Axis (degrees)
PLA 54 ± 20 415 ± 1587 59 ± 14 Time p = 0.15 G*T*Ge p = 0.34
LD 61 ± 17 438 ± 1653 60 ± 17 G*T p = 0.90
HD 200 ± 634 312 ± 1160 60 ± 17
Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Items in bold indicate a significant effect (p < 0.05) was observed
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Clinical blood safety markers
The effects of each treatment on clinical serum and
whole blood safety markers are listed in Tables 4, 5, 6
and 7.
Analyses for total cholesterol revealed no main ef-
fect for time (p = 0.07), but revealed a main effect for
time*group interaction (p = 0.001). Split-plot analyses
for total cholesterol regarding time*group*gender in-
teractions revealed no interaction (p = 0.86). Lower chol-
esterol levels (p ≤ 0.05) were revealed within the TC-HD
group at T2 and T3 compared to T1. Analyses for LDL
revealed a main effect for time (p = 0.001), and time*group
interaction (p = 0.024). Split-plot analyses for LDL re-
garding time*group*gender interactions revealed no inter-
action (p = 0.38). Significant differences (p ≤ 0.05) were
revealed within the TC-HD group at T2 and T3 compared
to T1. Analyses for HDL cholesterol, triglycerides, CHOL/
HDL ratio, and glucose levels revealed no main effects for
time, time*group interactions or time*group*gender inter-
actions (Table 4).
Analyses for serum creatinine revealed no main effect
for time (p = 0.33), or time*group interaction (p = 0.06),
although there was a time*group*gender interaction (p =
0.039). Additional post hoc analyses revealed creatinine
to increase within the male TC-LD subjects from T1 to
T3 (means: 1.05→ 1.15, p < 0.05), although levels remained
within clinical reference ranges. Analyses for serum
sodium revealed a main effect for time (p = 0.007), but no
time*group interaction (p = 0.67) or time*group*gender
interaction (p = 0.84). Additional post hoc analyses re-
vealed sodium decreased (p ≤ 0.05) at T2 compared to T1
in the TC-HD group. Analyses for serum chloride revealed
a main effect for time (p = 0.006), but no time*group inter-
action (p = 0.97) or time*group*gender interaction (p =
0.60). However, post-hoc analyses revealed no within- or
between-group changes in serum chloride (p > 0.05). Ana-
lyses for serum urea nitrogen, potassium, calcium and
carbon dioxide levels revealed no main effects for time,
time*group interactions or time*group*gender interactions
(Table 5).
Table 4 Serum clinical safety markers, part I
Variable T1 T2 T3 Time*group Time*group*gender
Cholesterol (mg/dL)
PLA 155 ± 37 154 ± 34 161 ± 32 Time p = 0.07 G*T*Ge p = 0.38
LD 151 ± 28 150 ± 26 160 ± 28 G*T p = 0.001
HD 174 ± 33 162 ± 33† 160 ± 32†
HDL (mg/dL)
PLA 49 ± 10 51 ± 12 55 ± 12 Time p = 0.08 G*T*Ge p = 0.99
LD 47 ± 11 50 ± 12 51 ± 12 G*T p = 0.16
HD 53 ± 16 49 ± 15 52 ± 16
LDL (mg/dL)
PLA 89.4 ± 28.9 83.4 ± 28.9 87.7 ± 23.9 Time p = 0.001 G*T*Ge p = 0.38
LD 85.0 ± 19.8 78.9 ± 17.8 86.9 ± 22.2 G*T p = 0.024
HD 103.0 ± 22.1 89.3 ± 20.5† 89.2 ± 19.9†
Cholesterol/HDL
PLA 3.3 ± 0.9 3.1 ± 0.9 3.0 ± 0.8 Time p = 0.19 G*T*Ge p = 0.48
LD 3.2 ± 0.8 3.0 ± 0.8 3.2 ± 0.9 G*T p = 0.77
HD 35 ± 0.9 3.3 ± 0.9 3.3 ± 0.9
Triglycerides (mg/dL)
PLA 67 ± 25 77 ± 31 73 ± 31 Time p = 0.21 G*T*Ge p = 0.73
LD 80 ± 45 93 ± 50 97 ± 50 G*T p = 0.63
HD 87 ± 39 92 ± 40 83 ± 36
Glucose (mg/dL)
PLA 86 ± 8 86 ± 8 86 ± 6 Time p = 0.14 G*T*Ge p = 0.44
LD 87 ± 7 86 ± 8 90 ± 8 G*T p = 0.55
HD 84 ± 9 86 ± 9 86 ± 7
Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Symbols: †, different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed
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Analyses for serum total protein revealed a main ef-
fect for time (p = 0.011), and time*group interaction
(p = 0.006), although no time*group*gender interaction
(p = 0.97). Additional post hoc analyses revealed total
protein to decrease in TC-HD from T1 to T3 (p < 0.05),
although levels remained within clinical reference ranges.
Analyses for Albumin revealed a main effect for time
(p = 0.023), but no time*group interaction (p = 0.17) or
time*group*gender interaction (p = 0.67). However, add-
itional post hoc analyses revealed no differences within-
or between groups. Analyses for serum globulin, bilirubin,
ALP, AST, or ALT levels revealed no main effects for time,
time*group interactions or time*group*gender interactions
(Table 6).
Analyses for hemoglobin revealed no main effect for
time (p = 0.56) or time*group interaction (p = 0.77),
but a time*group*gender interaction (p = 0.006). Add-
itional post hoc analyses revealed hemoglobin at T3
to be greater than T2 for PLA females (p < 0.05).
Analyses for hematocrit revealed no main effect for
time (p = 0.23) or time*group interaction (p = 0.85), but a
time*group*gender interaction (p = 0.049). Additional post
hoc analyses revealed hematocrit at T3 to be greater
than T2 for PLA females (p < 0.05). Analyses for platelet
count revealed a main effect for time (p = 0.005), but no
time*group interaction (p = 0.77) or time*group*gender
interaction (p = 0.16). Additional post hoc analyses re-
vealed platelets to increase in the PLA group from T1 to
T2 (p < 0.05).
Analyses for eosinophils revealed no main effect for
time (p = 0.62), but revealed a time*group interaction
(p = 0.041) and time*group*gender interaction (p = 0.002).
Table 5 Serum clinical safety markers, part II
Variable T1 T2 T3 Time*group Time*group*gender
Urea Nitrogen (mg/dL)
PLA 16 ± 4 15 ± 4 16 ± 5 Time p = 0.89 G*T*Ge p = 0.39
LD 14 ± 3 14 ± 3 15 ± 3 G*T p = 0.34
HD 15 ± 4 13 ± 4 14 ± 3
Creatinine (mg/dL)
PLA 1.18 ± 0.2 0.96 ± 0.2 0.97 ± 0.2 Time p = 0.33 G*T*Ge p = 0.046
LD 0.97 ± 0.1 1.02 ± 0.2 1.03 ± 0.2‡ G*T p = 0.06
HD 0.99 ± 0.2 1.01 ± 0.2 1.05 ± 0.2
Sodium (mmoL)
PLA 140.65 ± 3 139.85 ± 2 140.95 ± 2 Time p = 0.007 G*T*Ge p = 0.84
LD 141.22 ± 2 140.17 ± 2 140.95 ± 3 G*T p = 0.67
HD 141.19 ± 3 139.95 ± 2† 140.24 ± 2
Potassium (mmoL)
PLA 4.9 ± 0.4 4.7 ± 0.6 4.9 ± 0.5 Time p = 0.22 G*T*Ge p = 0.99
LD 5.0 ± 0.6 4.8 ± 0.4 4.9 ± 0.5 G*T p = 0.97
HD 4.9 ± 0.4 4.8 ± 0.4 4.9 ± 0.4
Chloride (mmoL)
PLA 105.60 ± 2 104.45 ± 2† 105.00 ± 2 Time p = 0.006 G*T*Ge p = 0.60
LD 105.89 ± 2 105.33 ± 2 104.84 ± 2 G*T p = 0.78
HD 105.24 ± 2 104.33 ± 2† 104.57 ± 2
Calcium (mg/dL)
PLA 9.7 ± 0.5 9.5 ± 0.4 9.6 ± 0.4 Time p = 0.37 G*T*Ge p = 0.74
LD 9.6 ± 0.3 9.6 ± 0.4 9.6 ± 0.3 G*T p = 0.20
HD 9.8 ± 0.3 9.7 ± 0.4 9.7 ± 0.3
Carbon Dioxide (mmoL)
PLA 24 ± 2 25 ± 2 24 ± 2 Time p = 0.65 G*T*Ge p = 0.95
LD 26 ± 2 26 ± 2 25 ± 2 G*T p = 0.85
HD 25 ± 2 25 ± 2 25 ± 2
Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Symbols: ‡, increase from corresponding T1 value within the male TC-LD group (p < 0.05); †, different from corresponding T1 value (p < 0.05). Items in bold indicate
a significant effect (p < 0.05) was observed
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Additional post hoc analyses revealed eosinophils to de-
crease in the PLA group from T1 to T2 (p < 0.05), but
additional gender post hocs revealed no between or within-
group differences. Analyses for white blood cells, red blood
cells, neutrophils, lymphocytes, monocytes, and basophils
revealed no main effects for time, time*group interactions
or time*group*gender interactions (Table 7).
Effects of Teacrine® on mood and concentration profiles
Analyses for POMS Vigor revealed a main effect for time
(p = 0.021), a time*group interaction (p = 0.006), and
a time*group*gender interaction (p = 0.044). Additional
post hoc analyses revealed a significant decrease in POMS
vigor in the TC-LD group from T1 to T2 (p < 0.05), but
was not different between T1 and T3. Moreover, this
POMS vigor increased from T2 to T3 within the female
TC-LD group (p < 0.05). Analyses for POMS fatigue
revealed a main effect for time (p = 0.031), but no
time*group interaction (p = 0.41) or time*group*gender
interaction (p = 0.79). Additional post hoc analyses for
POMS fatigue revealed no main effects between time
points. Analyses for total POMS score revealed a main
Table 6 Serum clinical safety markers, part III
Variable T1 T2 T3 Time*group Time*group*gender
Serum protein (g/dL)
PLA 7.0 ± 0.4 6.8 ± 0.4 7.0 ± 0.4 Time p = 0.011 G*T*Ge p = 0.97
LD 7.0 ± 0.5 6.8 ± 0.4 7.0 ± 0.4 G*T p = 0.006
HD 7.2 ± 0.4 7.0 ± 0.5 6.9 ± 0.3†
Albumin (g/dL)
PLA 4.6 ± 0.4 4.4 ± 0.4 4.5 ± 0.4 Time p = 0.023 G*T*Ge p = 0.67
LD 4.5 ± 0.3 4.5 ± 0.3 4.6 ± 0.3 G*T p = 0.17
HD 4.5 ± 0.3 4.5 ± 0.3 4.4 ± 0.2
Globulin (g/dL)
PLA 2.5 ± 0.3 2.4 ± 0.3 2.5 ± 0.2 Time p = 0.15 G*T*Ge p = 0.85
LD 2.4 ± 0.4 2.3 ± 0.3 2.5 ± 0.3 G*T p = 0.10
HD 2.6 ± 0.4 2.5 ± 0.4 2.4 ± 0.4
Albumin/Globulin
PLA 1.9 ± 0.3 1.9 ± 0.3 1.9 ± 0.3 Time p = 0.76 G*T*Ge p = 0.72
LD 1.9 ± 0.3 1.9 ± 0.3 1.9 ± 0.2 G*T p = 0.66
HD 1.8 ± 0.4 1.8 ± 0.4 1.8 ± 0.3
Bilirubin (mg/dL)
PLA 0.7 ± 0.3 0.7 ± 0.4 0.8 ± 0.5 Time p = 0.84 G*T*Ge p = 0.40
LD 0.7 ± 0.3 0.7 ± 0.3 0.6 ± 0.3 G*T p = 0.44
HD 0.7 ± 0.3 0.7 ± 0.3 0.6 ± 0.3
ALP (IU/L)
PLA 58 ± 17 57 ± 15 58 ± 15 Time p = 0.47 G*T*Ge p = 0.36
LD 53 ± 11 55 ± 12 57 ± 12 G*T p = 0.25
HD 65 ± 13 60 ± 15 62 ± 13
AST (IU/L)
PLA 21 ± 6 19 ± 5 20 ± 4 Time p = 0.12 G*T*Ge p = 0.66
LD 19 ± 5 18 ± 4 20 ± 7 G*T p = 0.81
HD 20 ± 6 18 ± 6 20 ± 7
ALT (IU/L)
PLA 17 ± 7 17 ± 6 17 ± 6 Time p = 0.34 G*T*Ge p = 0.45
LD 17 ± 7 17 ± 8 23 ± 24 G*T p = 0.19
HD 19 ± 8 17 ± 12 17 ± 6
Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Symbols: †, different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed
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Table 7 Clinical whole blood safety markers, part I
Variable T1 T2 T3 Time*group Time*group*gender
White blood cells (103 cells/μL)
PLA 6.0 ± 1.8 5.9 ± 1.7 6.2 ± 1.6 Time p = 0.52 G*T*Ge p = 0.18
LD 6.5 ± 1.5 6.3 ± 1.5 6.4 ± 1.5 G*T p = 0.52
HD 6.9 ± 1.5 6.5 ± 1.2 6.4 ± 1.8
RBC (106 cells/μl)
PLA 4.4 ± 0.4 4.4 ± 0.5 4.5 ± 0.4 Time p = 0.12 G*T*Ge p = 0.10
LD 4.8 ± 0.4 4.7 ± 0.4 4.8 ± 0.4 G*T p = 0.36
HD 4.8 ± 0.4 4.8 ± 0.5 4.8 ± 0.5
Hemoglobin (g/dL)
PLA 13.8 ± 1.0 13.7 ± 1.5 13.9 ± 1.3‡ Time p = 0.56 G*T*Ge p = 0.006
LD 14.4 ± 1.1 14.3 ± 1.1 14.5 ± 1.1 G*T p = 0.78
HD 14.2 ± 1.4 14.1 ± 1.3 14.1 ± 1.4
Hematocrit (%)
PLA 41 ± 3 41 ± 5 42 ± 3‡ Time p = 0.23 G*T*Ge p = 0.049
LD 43 ± 4 43 ± 3 44 ± 3 G*T p = 0.85
HD 43 ± 4 43 ± 4 43 ± 4
Platelet Count (103 particles/μL)
PLA 160 ± 46 191 ± 50† 204 ± 89 Time p = 0.005 G*T*Ge p = 0.16
LD 148 ± 61 176 ± 35 212 ± 71 G*T p = 0.77
HD 191 ± 40 216 ± 51 227 ± 41
Neutrophils (103 cells/μL)
PLA 3123 ± 843 3441 ± 1440 3679 ± 1443 Time p = 0.67 G*T*Ge p = 0.12
LD 3423 ± 920 3196 ± 862 3444 ± 881 G*T p = 0.28
HD 3631 ± 1417 3570 ± 921 3452 ± 1423
Lymphocytes (103 cells/μL)
PLA 1881 ± 543 1908 ± 479 1928 ± 492 Time p = 0.20 G*T*Ge p = 0.50
LD 2393 ± 698 2325 ± 738 2232 ± 681 G*T p = 0.13
HD 2624 ± 664 2200 ± 425 2384 ± 761
Monocytes (103 cells/μL)
PLA 426 ± 123 414 ± 150 412 ± 131 Time p = 0.97 G*T*Ge p = 0.07
LD 467 ± 149 498 ± 131 456 ± 156 G*T p = 0.65
HD 424 ± 184 399 ± 106 427 ± 123
Eosinophils (103 cells/μL)
PLA 157 ± 109 187 ± 125† 166 ± 115 Time p = 0.62 G*T*Ge p = 0.002
LD 187 ± 108 187 ± 102 189 ± 112 G*T p = 0.041
HD 225 ± 130 164 ± 87 181 ± 83
Basophils (103 cells/μL)
PLA 27 ± 12 24 ± 11 25 ± 12 Time p = 0.07 G*T*Ge p = 0.28
LD 30 ± 14 36 ± 19 25 ± 11 G*T p = 0.21
HD 32 ± 18 43 ± 23 33 ± 20
Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Symbols: ‡, increase from corresponding T2 value within the female PLA group (p < 0.05); †, different from corresponding T1 value (p < 0.05). Items in bold indicate
a significant effect (p < 0.05) was observed
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effect for time (p = 0.023), but no time*group interaction
(p = 0.50) or time*group*gender interaction (p = 0.62).
Additional post hoc analyses for total POMS score re-
vealed no main effects between time points. Analyses for
all other POMS variables revealed no main effects for
time, time*group interactions or time*group*gender inter-
actions (Table 8).
Analyses for VAS Energy revealed a main effect for
time (p < 0.001), but no time*group interaction (p = 0.12)
or time*group*gender interaction (p = 0.48). Additional
post hoc analyses for VAS Energy revealed that energy
decreased in PLA from time points T1 and T3, and T2
and T3 (p < 0.05). Furthermore, post hoc analyses for
VAS Energy revealed that energy decreased in the TC-
HD group from time points T1 and T3 (p < 0.05). Ana-
lyses for all other VAS variables revealed no main effects
for time, time*group interactions or time*group*gender
interactions.
Analyses for YALE 1 did not reveal a main effect for
time (p > 0.05), but revealed a time*group interaction
(p = 0.019) and did not reveal a time*group*gender
interaction (p = 0.73). Additional post hoc analyses for
total YALE 1 score revealed no main effects between
time points. Analyses for all other YALE variables re-
vealed no main effects for time, time*group interac-
tions or time*group*gender interactions.
Discussion
The primary objective of this study was to determine the
safety of TeaCrine® supplementation in human subjects
over an 8-week time course. As mentioned previously,
there is only limited amount of research on theacrine
Table 8 Mood and concentration profiles
Variable T1 T2 T3 Time*group Time*group*gender
POMS Tension
PLA 13 ± 4 13 ± 5 14 ± 4 Time p = 0.09 G*T*Ge p = 0.61
LD 13 ± 3 14 ± 5 14 ± 4 G*T p = 0.98
HD 14 ± 4 15 ± 4 15 ± 4
POMS Depression
PLA 16 ± 3 16 ± 4 17 ± 4 Time p = 0.12 G*T*Ge p = 0.47
LD 16 ± 2 17 ± 5 17 ± 3 G*T p = 0.55
HD 17 ± 2 18 ± 6 17 ± 5
POMS Anger
PLA 13.3 ± 2.4 13.9 ± 2.8 14.0 ± 3.7 Time p = 0.50 G*T*Ge p = 0.97
LD 13.0 ± 1.8 13.7 ± 4.2 13.5 ± 3.6 G*T p = 0.65
HD 13.7 ± 2.4 13.4 ± 2.1 13.5 ± 2.9
POMS Vigor
PLA 22 ± 5 22 ± 6 21 ± 6 Time p = 0.021 G*T*Ge p = 0.044
LD 23 ± 5 19 ± 6† 23 ± 6‡ G*T p = 0.006
HD 21 ± 5 20 ± 6 19 ± 5
POMS Fatigue
PLA 11 ± 3 12 ± 5 14 ± 5 Time p = 0.031 G*T*Ge p = 0.79
LD 11 ± 4 12 ± 5 11 ± 4 G*T p = 0.41
HD 13 ± 5 14 ± 5 15 ± 6
POMS Confusion
PLA 12 ± 2 13 ± 3 13 ± 3 Time p = 0.64 G*T*Ge p = 0.22
LD 13 ± 2 13 ± 2 13 ± 3 G*T p = 0.65
HD 13 ± 3 14 ± 4 13 ± 3
POMS Total
PLA 44 ± 13 45 ± 17 49 ± 16 Time p = 0.023 G*T*Ge p = 0.62
LD 43 ± 10 50 ± 20 45 ± 15 G*T p = 0.50
HD 51 ± 15 58 ± 23 58 ± 20
Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Symbols: ‡, increase from corresponding T2 value within the male TC-LD group (p < 0.05); †, different from corresponding T1 value (p < 0.05). Items in bold indicate
a significant effect (p < 0.05) was observed
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supplementation in humans making this study the first
of its kind. Our main findings of low- and high-dose
TeaCrine® supplementation included the following: 1)
supplementation was apparently safe and did not alter
hemodynamic measures or blood measures associated
with clinical safety, 2) there was no evidence of a tachy-
phylactic/habituation response that is typical of neuroac-
tive agents such as caffeine and other stimulants, 3)
supplementation in humans reduced LDL and total
cholesterol, and 4) supplementation did not affect body
composition measures. Our findings are described in
greater detail below.
TeaCrine® supplementation in humans does not affect
clinical safety markers
A variety of teas have been deemed safe for consumption
with minimal side effects such as Camellia Sinensis,
Camellia ptilophylla and Camellia assamica var. kucha
[5, 14, 15]. Specifically, the acute toxicity for theacrine
ingestion in mice has been previously reported [4] to be
an LD50 of 810.6 mg/kg, which would equate to roughly
4.0 g for an individual weighing 76 kg. Notwithstanding,
there has been recent concern that green tea extracts
(containing a variety of catechins) may be potentially
harmful in some individuals. Indeed, a comprehensive
review of the literature by US Pharmacoepia [16] reported
that 34 cases (up to the year 2007) existed concerning the
use of green tea products and their association with liver
damage. In 13 cases, serum enzymes suggestive of liver
damage were elevated following green tea supplementa-
tion. Herein, we report that all subjects supplementing
with low and high TeaCrine® dosages presented ALT, AST
and ALP levels that were within normal clinical ranges.
It should also be noted that chronic TeaCrine® sup-
plementation did not negatively alter the standard
hemodynamic variables (heart rate and blood pressure).
We are in agreement with Shan-Bing Li et al. [5] who
reported that theacrine had no observable effect on either
BP or HR in rats. Unlike theacrine, caffeine is the major
purine alkaloid in Camellia Sienesis and has shown to
increase BP [17]. Therefore, TeaCrine® supplementation
could be a safer alternative compared to caffeine when an
elevation in BP is a health concern. Collectively, our safety
data suggests that the doses used in the current study
were safe for human consumption.
The effects of TeaCrine® supplementation on self-perceived
vigor
In regards to cognitive measures, low dose TeaCrine®
supplementation slightly decreased POMS vigor from
baseline to 4 weeks of supplementation, but measures
returned to baseline after 8 weeks of supplementation.
Interestingly, theacrine feedings in mice have been shown
to reduce ambulatory activity [18], but at relatively low
doses; an effect which (in rodents) could also be a result
of reduced vigor. Additionally, it has been posited that
theacrine, the major purine alkaloid in Camellia assa-
mica var. kucha, has potent central nervous activation
on adenosine receptors that differ from caffeine [18].
Compared to theacrine, caffeine has arousal and stimulant
effects that are dependent on the A2AAR adenosine recep-
tors [19] whereas, theacrine could potentially act as an
endogenous sleep promoter on the A1 and A2A adenosine
receptors [20] at low doses, whereas higher doses may
result in increased CNS excitation and locomotor drive
[3]; a finding which could explain why POMS vigor scores
were slightly lower in low-dose theacrine-supplemented
participants. However, more research is needed to support
this hypothesis, as measures in the present study did
return to baseline by the week 8 data collection visit, and
the rodent data on neurophysiologic effects of theacrine
are mixed.
TeaCrine® supplementation in humans reduced LDL and
total cholesterol levels
It has been reported that polyphenols in tea could
inhibit the absorption of dietary cholesterol [21]. Add-
itionally, this effect has also been reported in tea cate-
chins, particularly their gallate esters, which are able to
reduce the absorption of cholesterol in the intestines
causing a hypocholesterolemic effect [22]. In a study in
hypercholesterolemia individuals [23] it was reported
that green tea had a lowering effect on LDL and total
cholesterol levels over twelve weeks. Similarly, we re-
ported decreases in total cholesterol and LDL cholesterol
in the HD group from baseline and time points week 4
and week 8, respectively, but all markers were within
normal clinical reference ranges. Therefore, as with other
similar studies reporting that tea extracts favorably affect
blood lipid levels, we report that high-dose theacrine
supplementation favorably alters serum total and LDL
cholesterol levels. Importantly, TeaCrine® supplementation
may be a viable ‘nutraceutical’ alternative to cholesterol-
lowering drugs but more research is needed in this area.
TeaCrine® supplementation does not affect body
composition
In a few studies, caffeine supplementation has been shown
to decrease body weight and fat mass [24]. Given that
theacrine is synthesized from the caffeine pathway via
hydration, oxidation and methylation [18, 25, 26] we
theorized it may potentially have similar effects. Moreover,
there is an abundance of literature on the efficacy of
Camellia sinensis teas such as green tea [24, 27, 28], but
there is no literature to our knowledge on theacrine
supplementation and its effects on body composition. We
report that TeaCrine® supplementation appeared to have
no observable effects on measures of body composition
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over the duration of the intervention. Reasons for no
effects observed within this study could include: 1) the
dose utilized was not high enough for humans, 2) longer
supplementation periods are needed for decrements in fat
mass to occur, and/or 3) unlike caffeine and other
thermogenic supplements, theacrine may be a ‘mild’
thermogenic supplement that does not elicit appre-
ciable weight loss over shorter supplementation periods
relative to other thermogenic aids (i.e., citrus aurantium,
caffeine and/or other combinations of ingredients). In this
regard, more research is needed to fully discern as to
whether TeaCrine®-containing supplements are effective
at managing body weight.
Conclusions
This is one of the first studies to our knowledge that has
studied the human safety, tachyphylactic response and
potential habituation to prolonged theacrine (TeaCrine®)
supplementation. One limitation to our study includes
the relatively short duration of the supplementation
protocol. Notwithstanding, we report that theacrine sup-
plementation did not affect body composition measures,
but reduced LDL and total cholesterol. The latter finding
has potential implications for theacrine supplementation
as a ‘nutraceutical’ modality for hypercholesterolemic in-
dividuals. Moreover, theacrine supplementation did not
alter hemodynamic measures or serum measures associ-
ated with clinical safety, and lower and higher doses
appear to be well-tolerated in humans over an 8 week
period.
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